In a report released today, Chris Shibutani from Goldman Sachs maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $299.00. The company’s shares closed last Wednesday at $217.69.
According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 23.7% and a 47.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Entrada Therapeutics Inc, Johnson & Johnson, and Merck & Company.
BioNTech SE has an analyst consensus of Moderate Buy, with a price target consensus of $295.09.
Based on BioNTech SE’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $6.09 billion and net profit of $3.21 billion. In comparison, last year the company earned revenue of $67.5 million and had a GAAP net loss of $210 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
Read More on BNTX:
- Why Wells Fargo Stock Could Beat the Market
- H.C. Wainwright Thinks Pliant Therapeutics’ Stock is Going to Recover
- J.P. Morgan Believes United Parcel (UPS) Won’t Stop Here
- InMode Announces 2022 Outlook & Preliminary 2021 Results
- H.C. Wainwright Maintains a Buy Rating on Mogo Finance Technology (MOGO)